Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring study

Jahr

2017

Autoren

Limmroth V, Ziemssen T, Lang M, Richter S, Wagner B, Haas J, Schmidt S, Gerbershagen K, Lassek C, Klotz L, Hoffmann O, Albert C, Schuh K, Baier-Ebert M, Wendt G, Schieb H, Hoyer S, Dechend R, Haverkamp W.

Verlag

BMC Neurol. 2017 Jan 18;17(1):11.

Link

https://doi.org/10.1186/s12883-016-0789-7

Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring study

Data on Ocrelizumab Treatment Collected by MS Patients in Germany Using Brisa App

Evaluation der langfristigen klinischen und ökonomischen Auswirkungen einer Behandlung mit Ofatumumab gegenüber Dimethylfumarat und Glatirameracetat bei Patienten mit schubförmiger Multipler Sklerose aus gesellschaftlicher Sicht in Deutschland

Comparison of time to clinically meaningful improvement in quality of life in neurological disorders in patients treated with natalizumab versus ocrelizumab

Sensitive Identification of Asymmetries and Neuromuscular Deficits in Lower Limb Function in Early Multiple Sclerosis

Neurofilaments as biomarkers in neurological disorders — towards clinical application